Article

Clinical factors predict metastatic progression post-RP

New Orleans--A combination of common clinical factors can accurately predict which patients who have biochemical failure after radical prostatectomy are likely to develop metastatic progression, said investigators from Memorial Sloan-Kettering Cancer Center, New York.

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
4 experts in this video
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
SBRT may offer a safe alternative to CFRT after prostatectomy
May 16th 2025

SBRT may offer a safe alternative to CFRT after prostatectomy

Hannah Clarke
Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Blurred interior of hospital - abstract medical background. | Image Credit: © jakkapan - stock.adobe.com
May 15th 2025

Real-time IRP monitoring may redefine safety and scope of flexible ureteroscopy

Professor Andreas Skolarikos Hannah Clarke
Professor Andreas Skolarikos shares his experience with the LithoVue Elite System.
Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD
May 2nd 2025

Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD

Amy M. Pearlman, MD
Experts discuss urgent priapism management strategies, emphasizing timely intervention and collaboration for optimal patient outcomes.
Published data support safety, efficacy of vaginal insert for SUI
May 14th 2025

Published data support safety, efficacy of vaginal insert for SUI

Hannah Clarke
Yōni.Fit bladder support was granted FDA 510(k) clearance in May 2024.
Enrollment progresses in study for cisplatin-induced hearing loss in testicular cancer
May 14th 2025

Enrollment progresses in study for cisplatin-induced hearing loss in testicular cancer

Hannah Clarke
ACOU085 will be administered in 1 ear, with a matching placebo injection in the respective contralateral middle ear.
© 2025 MJH Life Sciences

All rights reserved.